Novartis, after slimming down, boosts growth projection through the end of the decade
Fierce Pharma
NOVEMBER 21, 2024
As he introduced Novartis’ meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis’ status as a streamlined, “pure-play, innovative medicines” company and the succes | Novartis has adjusted its compound annual growth rate expectation from 5%-plus to 6%-plus through 2029. The Swiss company cited the momentum of its current growth drivers, which have paved the way for a strong sales performance this year.
Let's personalize your content